DFTX
Definium Therapeutics, Inc.
36.90$
+8.0%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q3 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -37.8% | +0.1% | +97.9% | – | – | -0.1% | +3.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | +324.1% | +49.8% | +97.9% | +52.7% | -16.5% | +18.5% | +11.7% | +20.7% | -5.9% | -8.9% | -16.7% | +13.6% | +42.7% | +17.3% | -10.7% | -12.6% | -3.2% | +31.0% | +17.4% | +26.6% | +7.3% | +27.6% | +3.9% | +8.2% | +23.8% | +17.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | +88.1% | -5.6% | -15.7% | +514.1% | -30.5% | +451.5% | -77.9% | -18.7% | +23.8% | -7.8% | +20.9% | -45.0% | +63.0% | +74.4% | -41.6% | +26.7% | -1.5% | -6.5% | -22.5% | +40.8% | -17.8% | +26.0% | +32.4% | -4.3% | +26.2% | +48.9% | – | |
| – | -10.8% | +47.6% | -47.6% | -23.9% | +45.4% | +94.0% | -52.9% | -43.2% | +4.3% | +27.6% | +876.2% | +161.9% | +38.9% | +27.1% | +341.3% | -58.1% | +226.5% | -61.9% | +1.9% | +5.4% | -8.4% | +0.2% | -18.2% | +50.1% | +39.9% | -25.9% | +2.7% | -2.4% | +12.8% | +1.4% | +30.9% | -0.9% | +27.2% | +11.7% | +4.2% | +24.5% | +26.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7.2% | +460.9% | -92.5% | – | – | – | – | +1.3% | +326.0% | – | – | +7.4% | +56.0% | -9.8% | -8.2% | +288.4% | -45.5% | +661.1% | -87.2% | -1.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.